-
Angiotensin II: Mechanism and Research Protocols
2026-09-05
Angiotensin II is an endogenous octapeptide and potent vasopressor that activates angiotensin receptors to regulate vascular tone, aldosterone release, and inflammatory remodeling. Its defined receptor signaling and research-use protocols support hypertension mechanism studies, vascular smooth muscle cell hypertrophy research, and abdominal aortic aneurysm models.
-
Microglia, Synapses, and Alcohol-Induced Seizures
2026-09-04
The reference study identifies hippocampal microglial activation as a mechanistic link between acute alcohol exposure and increased seizure susceptibility. Its intervention-based design suggests that microglia influence both inhibitory and excitatory synapse formation in CA1, providing a framework for studying neuroimmune control of network excitability.
-
DIDS Workflows for Metastasis and Ion-Channel Studies
2026-09-04
DIDS links chloride-transport pharmacology with a practical near-death tumor-cell workflow for studying prometastatic states. This guide emphasizes formulation, dose selection, orthogonal controls, and interpretation across cancer, vascular, and TRPV1 models.
-
SAA–GOT2 Signaling in Doxorubicin Cardiotoxicity
2026-09-03
This 2025 study identifies GOT2, a mitochondrial enzyme in the malate-aspartate NADH shuttle, as a functional target of salvianolic acid A in doxorubicin-induced cardiotoxicity. Its integrated omics, biophysical, genetic, and animal-model evidence links GOT2-dependent redox metabolism with improved cardiac function, while also indicating that salvianolic acid A can preserve antitumor activity in a lung-cancer model.
-
Resiniferatoxin (RTX): TRPV1 Research
2026-09-02
Resiniferatoxin (RTX) is an ultra-potent TRPV1 agonist that produces sustained cation influx and long-lasting desensitization of TRPV1-positive sensory endings. Its selective pharmacology supports preclinical research on osteoarthritis pain, neuropathic pain, postoperative pain, neurogenic inflammation, and context-dependent immune signaling.
-
Cyanidin Chloride: From Redox Mechanism to Translation
2026-09-02
A mechanistic, identity-aware guide to using Cyanidin Chloride in oxidative stress research, with practical assay strategy, interpretation of psoriasis-model evidence, and a disciplined path from reactive oxygen species scavenging to translational endpoints.
-
TMEM16F in Kupffer Cells Protects Against Listeria
2026-09-02
The reference study identifies Kupffer cell-expressed TMEM16F as a key determinant of host protection during Listeria monocytogenes infection, shifting the focus from lymphocytes to liver-resident macrophages. Its data connect calcium-activated lipid scrambling and plasma-membrane repair with control of liver inflammation, tissue injury, and metabolic disruption.
-
Alda 1 for ALDH2 Activation in Cardiac Research
2026-09-01
Alda 1 provides a practical way to test how ALDH2 activation links aldehyde detoxification with cardiomyocyte survival and proliferation. This guide translates recent pressure-overload findings into assay-ready workflows for cardiac ischemia research, ALDH2 variant comparisons, and carefully bounded radiation studies.
-
How GCG Disrupts SARS-CoV-2 N Condensation
2026-08-31
The reference study identifies RNA-triggered liquid–liquid phase separation of the SARS-CoV-2 nucleocapsid protein as a mechanistic feature of viral biology and shows that (-)-gallocatechin gallate disrupts this process. Its integrated sequence, biochemical, infection-associated, and replication analyses support viral condensates as a potential antiviral target, while also defining important limits for translation.
-
O-propargyl-puromycin (OPP) for Protein Synthesis
2026-08-31
O-propargyl-puromycin (OPP) converts short translation pulses into measurable nascent-protein signals for imaging, flow cytometry, immunoblotting, and enrichment. Its most informative use is comparative: linking global translation changes to mitochondrial stress, B-cell differentiation, and proteome remodeling rather than relying on a single protein endpoint.
-
(-)-JQ1: A Rigorous BET Control in AML Studies
2026-08-30
(-)-JQ1 is an inactive JQ1 stereoisomer that helps separate BET bromodomain-dependent biology from vehicle, stress, and compound-class effects. This workflow applies the control to BRD4 target gene modulation, inv(16) AML models, and translational epigenetics research without mistaking a negative control for a therapeutic agent.
-
Angiotensin II Workflows for Vascular Research
2026-08-29
Build reproducible cell and animal workflows around Angiotensin II to model oxidative endothelial injury, vascular smooth muscle cell hypertrophy, hypertension signaling, and vascular remodeling. This guide combines product-specific handling parameters with a reference-informed HUVEC assay strategy and practical troubleshooting.
-
S1P/S1PR3 Drives Neuronal Apoptosis After ICH
2026-08-28
A 2024 study identifies S1PR3 as a receptor-level driver of neuronal apoptosis after intracerebral hemorrhage, linking S1P signaling to TNF-α, PI3K/AKT, and caspase-3 activation. In vivo and cell-based findings suggest that S1PR3 antagonism may reduce secondary neuronal injury, while also highlighting the need for more selective and translational validation.
-
Fosinopril Sodium: From ACE Mechanism to Translation
2026-08-28
A translational framework for using Fosinopril sodium in hypertension research, cardiovascular disease models, blood pressure reduction studies, and renal hemodynamics modulation—with attention to prodrug activation, exposure control, and clinically meaningful endpoints.
-
Losartan Workflows for AT1 and TME Studies
2026-08-28
Use Losartan to connect angiotensin II receptor biology with vascular smooth muscle, fibroblast, and tumor-microenvironment assays. This workflow emphasizes receptor-aware dosing, collagen remodeling readouts, and controls that distinguish AT1 signaling from nonspecific cytotoxicity.